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ABSTRACT
Following an outbreak in Mecca Saudi Arabia in 2000, meningococcal strains expressing capsular group W (W) emerged as a major cause of invasive meningococcal disease (IMD) worldwide. 
The Saudi Arabian outbreak strain (Hajj clone) belonging to the ST-11 clonal complex (cc11) is similar to W cc11 causing occasional sporadic disease before 2000. Since 2000, W cc11 has caused large meningococcal disease epidemics in the African meningitis belt and endemic disease in South America, Europe and China. Traditional molecular epidemiologic typing suggested that a majority of current W cc11 burden represented global spread of the Hajj clone.  However, recent whole genome sequencing (WGS) analyses revealed significant genetic heterogeneity among global W cc11 strains. While continued spread of Hajj-related strains occurs in the Middle East, the meningitis belt and South Africa have co-circulation of the Hajj clone and other unrelated W cc11 strains and South America, the UK and France share a genetically distinct W c11 strain. Other W lineages persist in low numbers in Europe, North America and the meningitis belt. In summary, WGS is helping to unravel the complex genomic epidemiology of group W meningococcal strains. Wider application of WGS and strengthening of global IMD surveillance is necessary to monitor the continued evolution of group W lineages. There is need for a vaccine that is protective against group W in the meningitis belt.
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Neisseria meningitidis (meningococcus), an important cause of bacterial meningitis and sepsis worldwide shows dynamic changes in strain distribution over time []. The 13 African countries of the ‘meningitis belt’ have the highest incidence of endemic disease and periodic epidemics occur in this region (Figure 1) []. The major meningococcal virulence factor is the polysaccharide capsule, which is the target of capsular group-specific vaccines  ADDIN EN.CITE [] Capsular groups A, B, C, W (formerly W-135), Y and X cause almost all invasive meningococcal disease (IMD). Other virulence factors include major outer membrane proteins (OMP) PorA, PorB, FetA, FHbp and lipooligosaccharide  ADDIN EN.CITE [, ]. N. meningitidis undergoes genetic change through point mutation, phase variation, homologous recombination and acquisition of genetic material from both within and outside Neisseria species  ADDIN EN.CITE [, ]. These phenomena result in substantial genetic variability even among meningococcal isolates of the same lineage and facilitate emergence and persistence of virulent lineages  ADDIN EN.CITE [, ].
N. meningitidis capsular group W (W) was first observed among military recruits in the United States in the late 1960s  ADDIN EN.CITE [, ]. The pathogenic potential of group W was recognized by the mid-late 1970s  ADDIN EN.CITE [, ]. W emerged as a major global cause of IMD following  a global outbreak that began among Hajj pilgrims in Mecca, Saudi Arabia in 2000 which resulted in over 400 cases and 52 deaths; previously, group W had not been known to cause outbreaks []. The Hajj outbreak strain was characterized as clonal complex (cc) 11, PorA antigen gene type P1.5,2, with a distinct pulsed field gel electrophoresis (PFGE) pattern and 16S ribosomal RNA (16S) type 31  ADDIN EN.CITE []. Since 2000 several W epidemics have occurred in the meningitis belt and case clusters have been reported in South Africa, South America, Europe, United States and China  ADDIN EN.CITE []. Surveillance studies have shown that group W strains are associated with high high case fatality  ADDIN EN.CITE [, ], younger age groups  ADDIN EN.CITE [, ], and atypical clinical features such as arthritis and pericarditis  ADDIN EN.CITE [, ]. For example, the median age of patients with group W IMD in South Africa 2000-2005 was 5 years compared to 21 years among cases with group A disease  ADDIN EN.CITE []. In Burkina Faso in 2002 – 2003, 62% of W cases were in children <5years old compared to 7% of group A cases [].
Molecular surveillance studies using traditional genotyping techniques suggested that the current global burden of W cc11 represented continued spread of the epidemic Hajj clone  ADDIN EN.CITE [, ]. However, recent data based on whole genome sequencing (WGS) suggest that the molecular epidemiology of W cc11 is more complex []. In this review, we examine the global distribution and molecular characteristics of group W from 1970-2015 with emphasis on the emergence of endemic and epidemic W cc11 disease since 2000. 
Public Health Significance 
IMD is often a fatal disease; mortality rates range between 5-10% with survivors suffering from long term sequelae such as hearing loss and other neurologic deficits, limb amputation, and renal damage  ADDIN EN.CITE [, ]. Transmission is through close contact with airway droplets of asymptomatically colonized individuals. Risk factors for IMD are close contact with an IMD patient, cigarette smoking, kissing, immune complement deficiency and crowding in bars, dormitories or large human gatherings [].
Jafri et al [] classified global meningococcal disease incidence pattern into countries with epidemic and/or high endemic disease with incidence rates >10 cases per 100,000 population that comprise most African countries, Uruguay, New Zealand and Mongolia. The highest incidence rates of 100-1000 per 100,000 are witnessed during occasional epidemics across 21 countries [] in Africa collectively referred to as the ‘meningitis belt’ (Figure 1) []. Moderate endemic rates are between 2-10 cases per 100,000 population and occur in South Africa, some European countries, Brazil, Cuba and Australia. Remaining countries have low endemic rates (<2/100,000). 

Figure 1: Meningitis belt, 2006
 (Source: U.S. Centers for Disease Control and Prevention)

The epidemiologic pattern of meningococcal disease differs by capsular group over time []. Capsular group A is most common cause of  epidemic meningitis; for example, an outbreak of group A meningococcal disease in 1996 in the meningitis belt resulted in over 250,000 cases and 25,000 deaths []. Group B causes sporadic disease and small outbreaks in low to moderate endemic countries  ADDIN EN.CITE [, ] but is very uncommon in the meningitis belt. Group C also causes sporadic disease and small case clusters globally  ADDIN EN.CITE [], although group C strains occasionally cause large epidemics in the meningitis belt []. In recent decades, groups W and Y have emerged to cause significantly higher number of meningococcal disease cases globally  ADDIN EN.CITE [, , , ] while smaller group X  ADDIN EN.CITE [, ] epidemics have occurred in the meningitis belt.
IMD is a rapidly progressive disease that can cause death within 24-48 hours in previously healthy individuals or may lead to serious sequelae among survivors []. Additionally, outbreaks of meningococcal disease cause substantial economic cost and societal disruption  ADDIN EN.CITE [, ]. 
Vaccines remain the primary control strategy against meningococcal disease []. Laboratory surveillance of circulating meningococcal strains is critical for monitoring trends, informing vaccine policy, timely detection of outbreaks, and understanding the emergence of new IMD strains. 
Aims
This essay reviews the global distribution of group W meningococcal disease across five decades with a focus on the recent emergence of the W cc11 in recent decades as a major cause of meningococcal disease globally. A comparative review of current and historic molecular typing approaches used to classify group W strains is also presented. The aim is to provide Public Health personnel, microbiologists and epidemiologists with a reference framework that will assist in critical evaluation and interpretation of local meningococcal incidence and surveillance reports in order to make sound evidence-based public health decisions.   
Surveillance data presented in this essay, combined with the recent success with the control of group A disease in the meningitis belt [], make a compelling case for the introduction of a multivalent protein conjugate vaccine that covers group W strains in the meningitis belt where several thousand cases of IMD are caused by W strains. We also propose strengthening global meningococcal disease surveillance and broader application of whole genome characterization given the limitation of conventional genotyping approaches in discriminating group W strains. 


MOLECULAR CHARACTERISTICS OF GROUP W
Multilocus sequence typing (MLST) 
MLST is the method of choice for determining the genetic lineage of N. meningitidis  ADDIN EN.CITE []. Strains of the same sequence type (ST) share a common lineage and closely related STs are grouped under the same clonal complex (cc). Cc11 is a globally widespread, hyperinvasive cc comprised of strains expressing capsular groups B, C, W and Y  ADDIN EN.CITE [, ]. Historically, cc11 was more commonly associated with capsular group B in the 1960s  ADDIN EN.CITE [, ] and with group C from the early 1970s  ADDIN EN.CITE [, ]. Group W strains represented only a very small proportion of cc11 strains in the 1970s-1990s []. Following the Hajj 2000 epidemic [], cc11 became the predominant W lineage globally and the only  group W lineage associated with epidemic disease.  Sporadic group W belonging to other clonal complexes have occurred at low levels globally  ADDIN EN.CITE [, ] including cc22 in North America  ADDIN EN.CITE [, ] and Europe  ADDIN EN.CITE [, , ]; cc175 in the meningitis belt  ADDIN EN.CITE [, , ] and cc174 in Brazil  ADDIN EN.CITE [].
Outer membrane proteins (OMP), PorA, PorB, and FetA.
PorA and PorB are virulence determinants and the basis of serologic classification of meningococci. Meningococcal serotype and serosubtype are based on antigenic properties of PorB and PorA respectively []. Serologic classification has been superseded by gene sequence typing curated by the PubMLST database (pubmlst.org/neisseria/) []. Sequence variation within the porA gene, combined with MLST is a powerful tool for molecular surveillance  ADDIN EN.CITE [, ]. The porB [] and fetA  ADDIN EN.CITE [] genotypes are often used to further characterize invasive meningococcal strains. The W cc11 lineage is characterized by a remarkably stable outer membrane allelic profile P1.5,2:F1-1:2-2 (PorA VR1,VR2:FetA:PorB) despite global spread and different epidemiologic patterns over four decades  ADDIN EN.CITE [, , , , , , , ]. Although the P1.18 porA allele predominates among W cc22 strains  ADDIN EN.CITE [, , , ], OMP allelic profile variability among W cc22 isolates is consistent with non-clonal, sporadic disease (http://pubmlst.org/neisseria/ (​http:​/​​/​pubmlst.org​/​neisseria​/​​))  ADDIN EN.CITE [, ].
Pulse field gel electrophoresis (PFGE): 
PFGE [] has been used by some molecular epidemiologic studies  ADDIN EN.CITE [, , , ] to discriminate W cc11 Hajj outbreak strains from endemic strains.  Six of 19 (32%) sporadic pre-Hajj W cc11 isolates were indistinguishable by PFGE from the Hajj clone with remaining 13 isolates having >85% PFGE similarity to the Hajj clone  ADDIN EN.CITE []. Also, non-Hajj related W cc11 from Cameroon in 1999-2000 had 2-3 band differences from Hajj clone by PFGE []. It was not clear whether strains with  ≥3 PFGE band differences compared to the Hajj clone isolated from France [], Burkina Faso  ADDIN EN.CITE [] and Brazil  ADDIN EN.CITE [] in 2000-2003 represented continued expansion of the Hajj clone. Thus, PFGE was able to discriminate between W isolates belonging to different clonal complexes but was less discriminatory for epidemic and sporadic W cc11 strains. Despite this limitation, PFGE has been utilized to describe W strains as likely descendants of the Hajj clone  ADDIN EN.CITE [, ].
Whole Genome Sequencing (WGS)
WGS data are now publically available for several hundreds of genomes and are increasingly applied to the study of molecular epidemiology of global meningococcal lineages  ADDIN EN.CITE [, ]. In-depth genomic comparison of group B, C and W cc11 strains using genome-wide allelic profiling  ADDIN EN.CITE [, ] revealed that W cc11 strains were phylogenetically distinct from C and B strains. Phylogenetic studies  ADDIN EN.CITE [, ] also show that the W cc11 forms a distinct branch within cc11, suggesting that a majority of current and historic W cc11 strains shared a common origin, likely through a historic capsular switching event []. WGS studies have further discriminated W cc11 strains into a number of distinct phylogenetic clusters. Based on allelic profiles of 1546 core genomes, Lucidarme et al  ADDIN EN.CITE [] classified W cc11 into Anglo-French Hajj strains; Burkina Faso/North Africa strain and South American/UK strain (Table 1). Similarly, based on antigenic profiles, SNP and core genome phylogenetic analyses, Mustapha et al [] discriminated W cc11 strains linked to the Hajj outbreak from non-Hajj related endemic clusters and showed that the Hajj cluster acquired a number of unique virulence factors through allelic exchange. In summary, these studies demonstrate significant genetic diversity within W cc11 lineage and that genetically distinct sub-lineages were associated with different geographic and epidemiologic settings. 
Factor H binding protein (FHbp) 
FHbp is a meningococcal surface protein and one of the polysaccharide capsule-independent antigens used in vaccines that were developed for prevention of group B disease []. There is marked variability in the fHbp gene among W cc11 strains globally. The Hajj clone and descendant strains shared FHbp protein 9 (variant group 1); non-Hajj related W cc11 strains shared FHbp proteins belonging to variant groups 2 and 3; FHbp 22 is predominant among non-Hajj strains in Chile, Argentina, and Europe while strains from Africa and Brazil shared FHbp 23 and 151 respectively (http://pubmlst.org/neisseria/ (​http:​/​​/​pubmlst.org​/​neisseria​/​​))  ADDIN EN.CITE [, , , , ]. Substantial  fHbp gene diversity could be a common characteristic shared by cc11 strains regardless of capsular group given that group C cc11 strains from Canada were recently shown to exhibit extensive fHbp gene diversity  ADDIN EN.CITE [].
16S ribosomal RNA gene (16S) 
16S sequencing showed promise in discriminating the Hajj clone from sporadic W cc11. The Hajj clone contained 16S type 31 while sporadic W cc11 had 16S types 13 and 14  ADDIN EN.CITE [, ].
“Capsular switching” 
The expression of a different polysaccharide capsule through allelic exchange of capsular genes, has been linked with an increased incidence of meningococcal disease  ADDIN EN.CITE [, ]. In 1970-1999, cc11 genetic lineage was most commonly associated with invasive group C strains  ADDIN EN.CITE [, ]. This observation suggested that W cc11 strains arose through C→W capsular switch, although the true direction of the genetic exchange is unknown. 


GLOBAL INCIDENCE OF MENINGOCOCCAL GROUP W DISEASE
Group W IMD incidence, 1970 – 1999 
Capsular group W was associated with sporadic IMD cases globally in the 1970s through the mid-1990s. However, some surveillance data from the African meningitis belt, UK, Brazil and Taiwan suggest an increase in W cc11 in the mid- to late 1990s, predating the Hajj 2000 epidemic. 
Active surveillance in the United States identified W in 3% and 4% of invasive meningococcal isolates from 1989-1991 [] and 1992-1996  ADDIN EN.CITE [] respectively. In Canada W caused 3-6% of annual reported IMD cases in 1997-1999 [] and <1% of IMD cases in Quebec, 1991-1992  ADDIN EN.CITE []. In Australia 6% of 66 IMD isolates in 1971-1980[] and 8.2% of 110 IMD isolates in 1977-1987 [] belonged to group W. In Netherlands, W strains predominantly with PorB serotype 2a, represented <2.5% of all IMD isolates in 1959-1983  ADDIN EN.CITE [, ] and 1980-1990[]; W strains with phenotype 2a:P1.2,5 caused 3.5% of IMD in Poland, 1995-1996 []. In Italy, W strains represented 3.6% of 56 confirmed IMD cases in Italy 1994 [] and <1% in 1999-2001  ADDIN EN.CITE [] Sporadic W cases caused <8% of IMD cases in Norway and Denmark in the 1970s []; in Greece, 1996-1997  ADDIN EN.CITE []; East Germany, 1971-1984[] and Scotland 1972-1982 []. In England and Wales, average annual W cases increased to 42 cases/year in 1996/97-1998/99 compared to 18 cases/year in 1993/94-1995/96  ADDIN EN.CITE [] Some sporadic W strains from 1970-1999 from UK  ADDIN EN.CITE [], France [], Netherlands and Sweden  ADDIN EN.CITE [] were found to be genetically similar to the Hajj clone by various molecular typing methods  ADDIN EN.CITE [, , ]. In Sweden, P1.18 subtype, associated with cc22 was also common among sporadic W strains  ADDIN EN.CITE []. In summary, diverse W strains, including strains genetically similar to the Hajj clone caused a small proportion of IMD cases across Europe and North America during 1970-1999. 
In the African meningitis belt, W cc11 was identified in 3.1% of 349 endemic meningococcal disease strains from Senegal and Niger in 1981-1982 [] and 7.3% of 41 strains from the Gambia []. In 1992-1995, an unexpectedly high proportion of W cc11 (43%) was observed in a small sample of 14 endemic case isolates in Gambia  ADDIN EN.CITE []. In Brazil, W represented <2% of all meningococcal disease isolates from 1990-2001  ADDIN EN.CITE []. The proportion of Brazilian W cc11 isolates increased from 35% of 63 W isolates in 1990-1995 to 80% of 56 W isolates in 1996-1999  ADDIN EN.CITE [], while the proportion of cc174 declined from 52% to 16% among W isolates (Figure 2). All 67 W cc11 strains from Brazil in 1990-1999 were indistinguishable from the Hajj clone by porA and fetA genotyping but differed from the Hajj clone by both16S and PFGE  ADDIN EN.CITE []. 
Laboratory surveillance in Taiwan identified W cc11 among 30% (16/53) of confirmed IMD cases in 1996-1999 (Figure 2B)  ADDIN EN.CITE [] while rare W cases were reported from Malaysia [], Indonesia ADDIN EN.CITE [] and Thailand  ADDIN EN.CITE [] in the 1980s and 1990s. W strains have been identified among disease isolates in Saudi Arabia throughout the 1990s  ADDIN EN.CITE []. Group W comprised 13% of IMD case isolates in Saudi Arabia in 1994-1999  ADDIN EN.CITE [] and a small proportion (<10%) of IMD isolates in Egypt [], Israel [] and Kuwait [] in the 1980s and 1990s. These data demonstrate that W strains were endemic to the Middle East and W cc11 cases existed in parts of Asia since the 1980s.


Figure 2: Molecular typing of invasive capsular group W N. meningitidis in Brazil, 1990-2005. 






Figure 3: Distribution of confirmed N. meningitidis in Taiwan, 1996-2002. 
 Based on data from Chiou et al  ADDIN EN.CITE []. 
Group W incidence: 2000 and beyond
Saudi Arabia (Hajj) 2000-2001 
During the Hajj 2000 outbreak, over 400 cases of W cc11 disease were recorded among pilgrims and their close contacts across 16 different countries in Europe, Africa, Middle East, Southeast Asia and the United States (Figure 5). This represented the first known outbreak of group W disease  ADDIN EN.CITE [, , , ]. In 2001, a similar outbreak among pilgrims from Saudi Arabia occurred with 106 meningococcal cases reported that were indistinguishable from the 2000 Hajj clone by MLST, porA and fetA genotyping  ADDIN EN.CITE [, ] and by PFGE  ADDIN EN.CITE [, , ]. In 2002, a quadrivalent polysaccharide vaccine that covers W capsular antigen was made a visa requirement for all pilgrims traveling to Saudi Arabia, where no subsequent W outbreaks have been reported  ADDIN EN.CITE [, ]. 
Middle East: endemic W following Hajj epidemics.
Following the 200-2001 epidemics in Saudi Arabia, W became a leading cause of endemic meningococcal disease across the Middle East  ADDIN EN.CITE []. While Saudi Arabia witnessed a decline in meningococcal disease from 338 cases in 2000 to 6 cases in 2009, reports from Qatar, Oman, Kuwait and United Arab Emirates indicated that W was the most commonly identified meningococcal group in 2001-2009  ADDIN EN.CITE [, ]. It is unclear whether these endemic W cases represented spread and persistence of the Hajj clone. Laboratory surveillance of IMD strains identified W cc11 in 4.5% of 67 IMD isolates from Egypt, 1998-2003 [] and 38.1% of 333 confirmed pediatric IMD cases in Turkey, 2005-2012  ADDIN EN.CITE []. WGS studies demonstrate that endemic W cc11 strains from Turkey represent continued spread of the Hajj clone  ADDIN EN.CITE []. 
Africa: emergence of W cc11 epidemics
Cases of  W cc11 among Hajj pilgrims and their contacts were reported across Africa in  Morocco, Sudan, Chad, Central African Republic, and Burkina Faso in 2000 and 2001  ADDIN EN.CITE [, ]. In 2001, disease caused by W cc11 was equally as common as group A in a non-representative sample of cases from outbreaks in Burkina Faso and Niger []. In 2002, the largest known W epidemic occurred in Burkina Faso, with over 12,000 cases and 1,400 deaths  ADDIN EN.CITE []. More than 80% of cases were due to W cc11 strains [] with antigenic type P1.5,2 similar to the Hajj clone  ADDIN EN.CITE []. In 2003-2008, W cc11 epidemics subsided despite persistence of endemic cases  ADDIN EN.CITE [, ] []. Also, a substantial proportion of endemic W disease in the meningitis belt was caused by W cc175  ADDIN EN.CITE [, , ]. These data demonstrate the presence of other clonal W lineages in the meningitis belt post Hajj. Further W cc11 epidemics were recorded across the meningitis belt in 2009-2014  ADDIN EN.CITE [, , , ] making W the most commonly isolated capsular group across the meningitis belt in 2010-2014 (Figure 4). Genomic analyses  ADDIN EN.CITE [, , ] reveal that W cc11 in the meningitis belt were heterogeneous, with persistence of both the Hajj clone and strains unrelated to the Hajj outbreak. Hajj related W cc11 shared FHbp allele 9 while FHbp alleles 23 and 151 were predominant among non-Hajj endemic strains in the meningitis belt  ADDIN EN.CITE [, ]. Given the limited number of isolates characterized by whole genome sequencing, the relative contribution of the Hajj clone to W cc11 epidemics across the region is difficult to assess  ADDIN EN.CITE [, , , ].





Figure 4. Distribution of capsular groups among confirmed invasive meningococcal disease cases, meningitis belt 2003-2015.
On average, 9.3% of suspected meningitis cases had their cerebrospinal fluid (CSF) tested for common bacterial pathogens in 2005-2010 compared to 25.5% in 2011-2015. Others* depict all confirmed cases that were not group A or W in 2004-2009. Data from 2005 covers only weeks 1-18 while 2015 data covers the first 35 weeks of the year when most meningococcal disease cases occur. Based on publically available data from WHO (http://www.who.int/csr/disease/meningococcal/en/ (​http:​/​​/​www.who.int​/​csr​/​disease​/​meningococcal​/​en​/​​)) [].
Outside the meningitis belt, W strains, predominantly belonging to cc11, represented 9% of 350 IMD strains from South Africa in 1999-2002 []. In 2005, South Africa witnessed a doubling of meningococcal disease incidence due to an increase in W cc11  ADDIN EN.CITE [].  Similarly, meningococcal disease incidence attributed to W cc11 increased in neighboring Mozambique from 2005-2008  ADDIN EN.CITE []. Similar to the meningitis belt, South Africa also has co-circulation and persistence of non-Hajj endemic W cc11. More than 72% of W cc11 cases in South Africa in 2003-2013 were caused by strains representing continued spread of the Hajj clone [] while 28% were phylogenetically diverse, non-Hajj related isolates that shared FHbp alleles 22, 151 and 4 (http://pubmlst.org/neisseria/ (​http:​/​​/​pubmlst.org​/​neisseria​/​​)) []. Genetic heterogeneity among non-Hajj W cc11 strains in South Africa could represent evolution of a historical strain over several decades or may be a result of multiple introductions of global W cc11 lineages.

South America: Emergence of endemic W cc11 clusters.
Southern Brazil, Argentina and Chile witnessed the emergence of W cc11 as a major cause of endemic meningococcal disease after 2003  ADDIN EN.CITE []. Case clusters first appeared in southern Brazil where W represented 17.8% of all invasive strains in 2003-2005 compared to 3.2% in 1995-2002  ADDIN EN.CITE []. In Argentina, W cases increased from 7% in 2006 to 50% of all isolates in 2008-2011  ADDIN EN.CITE []. Similarly, the proportion of W cc11 increased in Chile from 6.6% in 2010 to 58.3% in 2012 []. Similar to UK, and France, W cc11 from Chile and Argentina also shared FHbp allele 22  ADDIN EN.CITE [, ] while Brazil W cc11 strains had FHbp allele 151.  
USA and Canada
No increase in endemic W in the United States was observed despite presence of Hajj related W cc11 cases in 2000  ADDIN EN.CITE []. W made up 2.3% (48/1979) of all isolates identified through sentinel surveillance in the United States during 2000-2010  ADDIN EN.CITE [, ]; cc22 predominated with only 2 cases of W cc11. However, a cluster of 14 W cc11 cases was reported in 2008-2009 in Florida  ADDIN EN.CITE []. WGS reveals that W cc11 from Florida were most genetically similar to South American strains []. Low incidence rates of W disease (0.01-0.05 per 100,000) have persisted in Canada from 1990-2011 accounting for 5% of all IMD cases []. In Quebec 2009-2013, W cc22 represented 3.8% of 263 confirmed IMD cases  ADDIN EN.CITE [].

Europe: emergence of endemic W cc11 clusters and persistence of sporadic W cc22 
Cases of W cc11 among returning pilgrims and their close contacts were reported across several European countries in 2000 and 2001  ADDIN EN.CITE [, ]. An overall increase in W disease occurred in France []. Among 101 W case isolates in France 45% (45/101) belonged to cc11 among which 32% (32/101) were indistinguishable from the Hajj clone by serotyping and PFGE []. In 2006-2008, W cc11 cases declined and were replaced by cc22  ADDIN EN.CITE []. A cluster of imported W cc11 cases from the meningitis belt was reported in France during 2012 []. A similar increase in W cases related to the Hajj outbreak was seen in the England and Wales 2000-2002  ADDIN EN.CITE []; W cases returned to pre-2000 levels in 2003 – 2008 and then increased again in 2009-2014, with 15% of all meningococcal disease cases in 2013-2014 being group W.[] Over 67% of all W cases in the UK 2010-2013 belonged to cc11 while cc22 persisted as a cause of sporadic disease []. In Spain, W cc22 strains represented 1.6% of IMD cases in the Basque region, 1990-2004 []. Likewise in Italy, W persisted as a cause of sporadic IMD causing for 2.6% of IMD cases in 2006-2014  ADDIN EN.CITE [, ] where cc22 predominated with fewer W cc11 isolates []. 
Recent W cc11 case clusters from the UK, Ireland and France 2009-2015 formed a common phylogenetic cluster with strains from Brazil, Chile and Argentina  ADDIN EN.CITE []. These data suggest that European W cc11 clusters represent continuing spread of the South American strain. 
Asia
In Singapore, Hajj related and endemic W cc11 cases were reported in 2000-2002 [] but have not been reported since 2003 suggesting disappearance of endemic W cc11 []. In Taiwan 2000-2001, average W cc11 case isolates increased to 34 cases/year compared to 4 cases/year in 1996-1999  ADDIN EN.CITE []. Also, endemic W cc11 cases emerged in China (2011-2012) where 24.4% (11/45) confirmed IMD in 2011 -2012 cases were W cc11 []. Rare group W cases belonging to cc4821 have also occurred in China  ADDIN EN.CITE []. It is unclear whether W cc11 in Taiwan and China represent expansion of local endemic strains or continued global spread of the Hajj clone. A few W cases (<4) were also reported in Malaysia [], India [] and Japan [].  In Korea, a cluster of three of W cc11 cases whose OMP genotype (P1.5-1,2-2:F3-9) differed  from that of other global W cc11 strains was identified among military recruits []. These data demonstrate the complex molecular epidemiology of W strains, and the need to strengthen molecular surveillance of N. meningitidis in parts of Asia.
Australia and New Zealand





Figure 5. Global occurrence of capsular group W cc11 meningococcal disease, 2000-2014.  








Epidemic W cc11 IMD began with the 2000 Hajj outbreak. However, an upward trend in W cc11 sporadic cases occurred in the mid to late 1990s in the meningitis belt  ADDIN EN.CITE [, ], Brazil  ADDIN EN.CITE [], UK  ADDIN EN.CITE [] and Taiwan  ADDIN EN.CITE []. Application of WGS to molecular surveillance of meningococcal disease revealed that several W cc11 case clusters arose independent of the Hajj epidemic consistent with global multifocal emergence of W cc11  ADDIN EN.CITE [, , ]. W cc11 was found to comprise a number of genetically and geographically diverse sub-lineages and different sub-lineages could coexist within the same country at the same time. W cc22 in Europe and North America and cc175 in Africa have persisted as a cause of a minority of disease cases. 

The Hajj, an annual gathering of over 2 million people from around the world is an ideal setting for the selection and rapid global dissemination of virulent meningococci. For example, in 1987, a Hajj-related meningococcal outbreak facilitated the spread of virulent group A cc5 meningococci from south Asia to sub-Saharan Africa []. Excessive crowding during the Hajj may have facilitated rapid, intense transmission of an antigenically novel strain within an immunologically naïve population []. The Hajj clone and its descendants shared a number of recombination events leading to allelic exchange within fHbp gene and metabolic genes, nor and aniA. These methobolic genes may be involved in nasopharyngeal survival of meningococci and could have played a role in increased virulence of the Hajj clone. It is also hypothesized that the polysaccharide group A/C vaccine requirement for Hajj pilgrims in the 1990s could have led to selection of  a group W strain that had undergone capsular switching  ADDIN EN.CITE [, ]. Existence of multiple endemic clusters caused by strains unrelated to the Hajj epidemic suggests that different genetic and/or environmental factors could be responsible for emergence and persistence of different sub-lineages in different epidemiologic settings. 
CONCLUSION
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